News EPFL

Appointment of EPFL professors

Published:10.12.21 — The Board of the Swiss Federal Institutes of Technology has announced the appointment of professors at EPFL.

“The EU is hitting the limits in the US system it's modeled after”

Published:08.12.21 — Policymakers need to reconsider the European Union’s heavy promotion of cross-border mobility if they want to preserve cohesion among member states, according to a new book by three researchers drawing on urban sociology studies carried out at EPFL.

Rigidifying cancer cells for better immunotherapy

Published:07.12.21 — EPFL scientists have found that stiffening the membranes of cancer cells can lead to improved immunotherapy outcomes. Preclinical tests show that it can increase long-term survival rates to nearly 50%.

New program supports femtech entrepreneurs

Published:06.12.21 — Thirty startups have raised CHF 60 million in funding through Tech4Eva, continental Europe’s first program designed specifically for entrepreneurs in the field of femtech, or technology for women’s health. On 7 December, Switzerland’s first femtech conference will mark the end of Tech4Eva’s inaugural year – and kick off the next funding round.

A best practices guide to PhD programs at EPFL

Published:03.12.21 — EPFL has published a guide that sets out the rules of its PhD programs, as well as the rights and responsibilities of PhD students and their thesis supervisors.

Molecular device turns infrared into visible light

Published:03.12.21 — Researchers at EPFL, China, Spain and the Netherlands have built a micro-device that uses vibrating molecules to transform invisible mid-infrared light into visible light. The breakthrough ushers in a new class of compact sensors for thermal imaging and chemical or biological analysis.

Loop Medical develops needle-free device for collecting blood samples

Published:02.12.21 — Loop Medical, based at EPFL’s Innovation Park, has just closed a $6.4 million financing round to support the US market entry of its needle-free blood-sampling device.